Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR's RISE Registry.
Despite strong recommendations for routine measurement of rheumatoid arthritis (RA) disease activity and associated treatment changes to attain remission/low disease activity, the measurement tools that clinicians use to evaluate RA patients' disease activity and frequency of treatment change has not been well characterized. Using 1/2016-6/2017 RISE registry data, we identified eligible patients as follows: 1) age ≥18; 2) RA diagnoses (ICD-9/10-CM codes); 3) ≥2 RISE visits; 4) ≥1 RA disease activity measure in 2016. We classified patients' index visit drug use as monotherapy or combination therapy with conventional synthetic and biologic disease-modifying antirheumatic drugs (csDMARDs and bDMARDs, respectively). Outcomes include change in treatment over 12 months. Mixed models identified factors associated with treatment change. Among 50,996 eligible patients, 27,274 were with longitudinal data. The commonly used measures were RAPID3 (78.9%) and CDAI (34.2%). The frequency of treatment change during follow-up was relatively low (35.6%-54.6%), even for patients in moderate/high disease activity by RAPID3 or CDAI. Older patients (age ≥75, adjusted odds ratio [aOR]=0.63, 95% CI 0.50-0.78) and those already receiving combination therapy with csDMARDs (aOR=0.45, 95% CI 0.33-0.61) or combo therapy with bDMARDs (aOR=0.30, 95% CI 0.24-0.38) were less likely to change RA treatment even after multivariable adjustment. Using ACR's national RISE registry, one- to two-thirds of RA patients failed to change their treatment, even when in moderate/high disease activity. Multi-modal interventions directed both at patients and providers are needed to encourage shared decision making, goal directed care, and to overcome barriers to treatment escalation.